Antisense therapeutics in oncology: Current status

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 2035-2042

  Farooqi, Ammad Ahmad ^a   ur Rehman, Zia ^b   Muntane, Jordi ^c,d  

^a RASHID LATIF MEDICAL COLLEGE   (Pakistan)

^b KOHAT UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Pakistan)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antisense oligonucleotide; Antisense therapy; DNAzymes; Liposomes; miRNA; siRNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; CISPLATIN; CUSTIRSEN; CYTARABINE; DEOXYRIBOZYME; DOCETAXEL; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EZN 2968; EZN 3920; EZN 4176; GATAPARSEN; GEFITINIB; HYBRID PROTEIN; IDARUBICIN; LAPATINIB; LIPID; LIPOFECTAMINE; LIPOSOME; MICRORNA; MICRORNA 214; NANOPARTICLE; NUCLEIC ACID; POLYAMIDOAMINE; PREDNISONE; PROTEIN; SMALL INTERFERING RNA; STABLE NUCLEIC ACID LIPID PARTICLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTISENSE THERAPY; CANCER CELL; CANCER GENE THERAPY; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; DOWN REGULATION; DRUG DEVELOPMENT; DRUG PENETRATION; DRUG SENSITIZATION; DRUG TARGETING; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TARGETING; HUMAN; LIVER CIRRHOSIS; MEDICAL RESEARCH; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TREATMENT RESPONSE; WEST NILE FEVER;

EID: 84908395519     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S49652     Document Type: Review

References (76)

1. Scholz C, Wagner E. Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. J Control Release. 2012;161(2):554–565.
2. DiFiglia M, Sena-Esteves M, Chase K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropa-thology and behavioral defcits. Proc Natl Acad Sci U S A. 2007;104(43): 17204–17209.
3. de Fougerolles A, Novobrantseva T. siRNA and the lung: research tool or therapeutic drug? Curr Opin Pharmacol. 2008;8(3):280–285.
4. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med. 2005;11(1):50–55.
5. Niu XY, Peng ZL, Duan WQ, Wang H, Wang P. Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer. 2006;16(2):743–751.
6. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005;11(3):263–270.
7. Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA. 2003;9(9):1034–1048.
8. Judge AD, Robbins M, Tavakoli I, et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest. 2009;119(3):661–673.
9. Judge AD, Bola G, Lee AC, MacLachlan I. Design of non inflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther. 2006;13(3):494–505.
10. Vornlocher H P, Hadwiger P, Zimmerman T, et al, inventor; Alnylam Pharmaceuticals, Inc., assignee. Nuclease-resistant double-stranded RNA for RNA interference. United States patent WO 2005115481. August 12, 2005.
11. Layzer JM, McCaffrey A P, Tanner AK, Huang Z, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. RNA. 2004;10(5): 766–771.
12. Terrazas M, Kool ET. RNA major groove modifications improve siRNA stability and biological activity. Nucleic Acids Res. 2009;37(2): 346–353.
13. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173–178.
14. Xu Y, Szoka FC Jr. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry. 1996;35(18):5616–5623.
15. Torchilin V P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–160.
16. Boussif O, Lezoualc’h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A. 1995;92(16):7297–7301.
17. Putnam D. Polymers for gene delivery across length scales. Nat Mater. 2006;5(6):439–451.
18. Soriano P, Dijkstra J, Legrand A, et al. Targeted and nontargeted liposomes for in vivo transfer to rat liver cells of a plasmid containing the prepro-insulin I gene. Proc Natl Acad Sci U S A. 1983;80(23):7128–7131.
19. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A. 1987;84(21):7413–7417.
20. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. Lipid-based nanotherapeutics for siRNA delivery. J Intern Med. 2010;267(1):9–21.
21. Rehman Zu, Zuhorn IS, Hoekstra D. How cationic lipids transfer nucleic acids into cells and across cellular membranes: recent advances. J Control Release. 2013;166(1):46–56.
22. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23(8):1002–1007.
23. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441(7089):111–114.
24. Huang AJ. Suppression of keratoepithelin and myocilin by small interfering RNA (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2007;105:365–378.
25. Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008;26(4):431–442.
26. Kumar P, Lee SK, Shankar P, Manjunath N. A single siRNA suppresses fatal encephalitis induced by two different faviviruses. PLoS Med. 2006;3(4):e96.
27. Reschner A, Shim YH, Dubois P, et al. Evaluation of a new biocompat-ible poly(N-morpholino ethyl methacrylate)-based copolymer for the delivery of ruthenium oligonucleotides, targeting HPV16 E6 oncogene. J Biomed Nanotechnol. 2013;9(8):1432–1440.
28. Ding H, Helguera G, Rodríguez JA, et al. Polymalic acid nanobio-conjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer. J Control Release. 2013;171(3):322–329.
29. Yo u X, Yang YC, Ke X, Hong SL, Hu GH. Fluorescence visualization screening for EBV-LMP1-targeted DNAzymes. Otolaryngol Head Neck Surg. 2014;150(2):251–258.
30. Gomes-da-Silva LC, Santos AO, Bimbo LM, et al. Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment. Int J Pharm. 2012;434(1–2):9–19.
31. Costa PM, Cardoso AL, Mendonça LS, et al. Tumor-targeted chlorotoxin-coupled nanoparticles for nucleic acid delivery to glioblas-toma cells: a promising system for glioblastoma treatment. Mol Ther Nucleic Acids. 2013;2:e100.
32. Najar AG, Pashaei-Asl R, Omidi Y, Farajnia S, Nourazarian AR. EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line. Asian Pac J Cancer Prev. 2013;14(1):495–498.
33. Nourazarian AR, Najar AG, Farajnia S, Khosroushahi AY, Pashaei-Asl R, Omidi Y. Combined EGFR and c-Src antisense oligodeoxynucleotides encapsulated with PAMAM denderimers inhibit HT-29 colon cancer cell proliferation. Asian Pac J Cancer Prev. 2012;13(9):4751–4756.
34. Nourazarian AR, Pashaei-Asl R, Omidi Y, Najar AG. c-Src antisense complexed with PAMAM denderimes decreases of c-Src expression and EGFR-dependent downstream genes in the human HT-29 colon cancer cell line. Asian Pac J Cancer Prev. 2012;13(5): 2235–2240.
35. Peng C, Sun Q, Fang Y, Cong B, Zhao X. VEGF-C antisense oligoxyde-nucleotide suppression of invasive ability of the A-549 lung carcinoma cell line. Asian Pac J Cancer Prev. 2011;12(8):2097–2099.
36. Witort E, Lulli M, Carloni V, Capaccioli S. Anticancer activity of an antisense oligonucleotide targeting TRADD combined with protea-some inhibitors in chemoresistant hepatocellular carcinoma cells. J Chemother. 2013;25(5):292–297.
37. Matsumoto H, Yamamoto Y, Shiota M, et al. Cotargeting androgen receptor and clusterin delays castrate-resistant prostate cancer progression by inhibiting adaptive stress response and AR stability. Cancer Res. 2013;73(16):5206–5217.
38. Ye Y, Zhou X, Li X, Tang Y, Sun Y, Fang J. Inhibition of epidermal growth factor receptor signaling prohibits metastasis of gastric cancer via downregulation of MMP7 and MMP13. Tumour Biol. Epub August 2, 2014.
39. Ito K, Semba T, Uenaka T, Wakabayashi T, Asada M, Funahashi Y. Enhanced anti-angiogenic effect of E7820 in combination with erlo-tinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models. Cancer Sci. 2014;105(8):1023–1031.
40. Rytelewski M, Tong JG, Buensuceso A, et al. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. Mol Oncol. Epub June 6, 2014. pii: S1574-7891(14)00124-00120.
41. Sun L, Liu L, Liu X, et al. MGr1-Ag/37LRP induces cell adhesion-mediated drug resistance through FAK/PI3K and MAPK pathway in gastric cancer. Cancer Sci. 2014;105(6):651–659.
42. Ovcharenko D, Kelnar K, Johnson C, Leng N, Brown D. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res. 2007;67(22):10782–10788.
43. Imam JS, Buddavarapu K, Lee-Chang JS, et al. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene. 2010;29(35):4971–4979.
44. Noguchi S, Yamada N, Kumazaki M, et al. socs7, a target gene of microRNA-145, regulates interferon-β induction through STAT3 nuclear translocation in bladder cancer cells. Cell Death Dis. 2013;4:e482.
45. He L, He X, Lim L P, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447(7148):1130–1134.
46. Garofalo M, Jeaon YJ, Nuovo GJ, et al. MiR-34a/c-dependent PDGFR-α/β downregulation inhibits tumorigenesis and enhances TRAIL-induced apoptosis in lung cancer. PLoS One. 2013;8(6):e67581.
47. Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene. 2008;27(27):3845–3855.
48. Garofalo M, Di Leva G, Romano G, et al. mir-221 and 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009;16(6):498–509.
49. Razumilava N, Bronk S F, Smoot RL, et al. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology. 2012;55(2): 465–475.
50. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007;26(42): 6133–6140.
51. Patron J P, Fendler A, Bild M, et al. MiR-133b targets antiapoptotic genes and enhances death receptor-induced apoptosis. PLoS One. 2012;7(4):e35345.
52. Lu Q, Lu C, Zhou G P, Zhang W, Xiao H, Wang XR. MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. Urol Oncol. 2010;28(6):635–641.
53. Incoronato M, Garofalo M, Urso L, et al. miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res. 2010;70(9):3638-3646.
54. Liu J, Ma L, Li C, Zhang Z, Yang G, Zhang W. Tumor-targeting TRAIL expression mediated by miRNA response elements suppressed growth of uveal melanoma cells. Mol Oncol. 2013;7(6):1043-1055.
55. Zhang ZC, Li YY, Wang HY, et al. Knockdown of miR-214 promotes apoptosis and inhibits cell proliferation in nasopharyngeal carcinoma. PLoS One. 2014;9(1):e86149.
56. Seca H, Lima RT, Lopes-Rodrigues V, Guimaraes JE, Almeida GM, Vasconcelos MH. Targeting miR-21 induces autophagy and chemo-sensitivity of leukemia cells. Curr Drug Targets. 2013;14(10): 1135-1143.
57. Takahashi M, Yamada N, Hatakeyama H, et al. In vitro optimization of 2'-OMe-4'-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle. Nucleic Acids Res. 2013;41(22):10659–10667.
58. Hatakeyama H, Murata M, Sato Y, et al. The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. J Control Release. 2014;173:43-50.
59. Yan LX, Wu QN, Zhang Y, et al. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res. 2011;13(1):R2.
60. Brognara E, Fabbri E, Aimi F, et al. Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells. Int J Oncol. 2012;41(6):2119-2127.
61. Leucci E, Zriwil A, Gregersen LH, et al. Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. Oncogene. 2012;31(49):5081-5089.
62. Luo X, Feng M, Zhu X, Li Y, Fei J, Zhang Y VEGF depletion enhances bcr-abl-specifc sensitivity of arsenic trioxide in chronic myelogenous leukemia. Hematology. 2013;18(6):334-340.
63. Kim JE, Yoon S, Mok H, Jung W, Kim DE. Site-specific cleavage of mutant ABL mRNA by DNAzyme is facilitated by peptide nucleic acid binding to RNA substrate. FEBS Lett. 2012;586(21):3865-3869.
64. Haririan M, Kaviani S, Soleimani M, Ghaemi SR, Delalat B, Atashi A. Morpholino oligo antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by morpholino oligo antisense in BCR-ABL(+) cells. Hematology. 2012;17(1):28-34.
65. Van Hauwermeiren F, Vandenbroucke RE, Grine L, et al. Antisense oligonucleotides against TNFR1 prevent toxicity of TNF/IFNytreatment in mouse tumor models. Int J Cancer. 2014;135(3):742-750.
66. Wu Y, Zhang Y, Wang M, et al. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models. Mol Cancer Ther. 2013;12(4):427–437.
67. Han S, Cai Z, Peng L, et al. Polyamidoamine dendrimer liposome-mediated survivin antisense oligonucleotide inhibits hepatic cancer cell proliferation by inducing apoptosis. Tumour Biol. 2014;35(5):5013-5019.
68. Biragyn A, Bodogai M, Olkhanud PB, et al. Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4+ Tregs. J Immunother. 2013;36(4):258-267.
69. Bianchini D, Omlin A, Pezaro C, et al. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer. 2013;109(10):2579-2586.
70. Erba HP, Sayar H, Juckett M, et al. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest New Drugs. 2013;31(4):1023-1034.
71. Blumenstein B, Saad F, Hotte S, et al. Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. Cancer Med. 2013;2(4):468-477.
72. Laskin JJ, Nicholas G, Lee C, et al. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol. 2012;7(3):579–586.
73. Wiechno P, Somer BG, Mellado B, et al. A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with frst-line docetaxel/prednisone in patients with castration-resistant prostate cancer. Eur Urol. 2014;65(3):516–520.
74. Jeong W, Rapisarda A, Park SR, et al. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2014;73(2):343–348.
75. Ott PA, Chang J, Madden K, et al. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemother Pharmacol. 2013;71(1): 183–191.
76. Sen M, Thomas SM, Kim S, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2012;2(8):694–705.